Stockreport

LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223) [Yahoo! Finance]

LAVA Therapeutics N.V. - Ordinary Shares  (LVTX) 
PDF LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma de [Read more]